


## LY3509754

Cat. No.:	HY-139206
CAS No.:	2452464-73-0
Molecular Formula:	C <sub>24</sub> H <sub>27</sub> F <sub>5</sub> N <sub>8</sub> O <sub>4</sub>
Molecular Weight:	586.51
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    6 months -20°C    1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (426.25 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div><div>Mass</div></div>	1 mg	5 mg	10 mg
		1 mM	1.7050 mL	8.5250 mL	17.0500 mL
		5 mM	0.3410 mL	1.7050 mL	3.4100 mL
		10 mM	0.1705 mL	0.8525 mL	1.7050 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC <sub>50</sub> values of <9.45 nM and 9.3 nM in alphasisa assay and HT-29 cells [1].
IC <sub>50</sub> & Target	IL-17
In Vivo	LY3509754 (example 24) possesses high oral bioavailability (F=107%) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

---

- Bioact Mater. 37, July 2024, Pages 51-71.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. COATES DAVID ANDREW, et al. IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS. Patent WO2020146194.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA